OcuLief^®

OcuLief® is a patented system that involves the injection of a liquid formulation into the eye using a narrow gauge (25G) needle.

This formulation simultaneously undergoes two kinetic processes: phase inversion and, upon exposure to visible light (405 nm), cross- linking to form a photo-crosslinked implant.

The OcuLief® implant enables sustained release of the drug and is particularly suitable for biologics, peptides, large and small molecules that often necessitate higher release rates of ≥2 µg/day for a duration of 3 to 12 months.

Factors influencing the rate and duration of drug release from OcuLief® include the choice of macromers, excipients, drug loading, crosslink density and volume of formulation used.